Prucalopride inhibits lung cancer cell proliferation, invasion, and migration through blocking of the PI3K/AKT/mTor signaling pathway

Abstract

Lung cancer is the main cause of cancer incidence and mortality around the world. Prucalopride is an agonist for the 5-hydroxytryptamine 4 receptor, but it was unknown whether prucalopride could be used to treat lung cancer. To investigate the biological effects of prucalopride on proliferation, apoptosis, invasion, and migration of lung cancer cells, and its underlying molecular mechanism in the progression of lung cancer, we performed this study. The Cell Counting Kit 8 assay was used to measure the proliferation of A549/A427 lung cancer cells treated with prucalopride. Transwell assay was applied to evaluate cell invasion and migration. Cell apoptosis was detected by flow cytometry and Western blot analyses. The expression levels of related proteins in the PI3K/AKT/mTor signaling pathway were analyzed by Western blotting. Prucalopride inhibited the proliferation, invasion, and migration of A549/A427 human lung cancer cells. It also induced autophagy and apoptosis and decreased the expression of the phosphorylated protein kinase B (AKT) and mammalian target of rapamycin (mTor) in these cells. This study implied an inhibitory role for prucalopride in the progression of human lung cancer.

RETRACTED ARTICLE: TGF-β is associated with poor prognosis and promotes osteosarcoma progression via PI3K/Akt pathway activation

“…The PI3K/mTOR signaling pathway facilitates the proliferation, invasion/migration, vascularization, and tumorigenicity of cancer cells [24][25][26][27]. si-TGF-β treatment markedly attenuated p-PI3K and p-Akt expression in U2OS and MG-63 cells (Figure 5(a)), indicating that the PI3K/mTOR signaling pathway may mediate the effects of TGF-β on osteosarcoma progression.…”

ET-1 promotes the growth and metastasis of esophageal squamous cell carcinoma via activating PI3K/Akt pathway

“…Increasing evidence confirmed that the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) signaling pathway, as a regulatory factor of tumor progression, was activated in various cancers ( 15 , 16 ). For example, inhibition of the PI3K/Akt signaling pathway suppressed cell proliferation, invasion and migration of colorectal cancer ( 17 ), lung cancer ( 18 ), oral squamous cell carcinoma ( 19 ), hepatocellular carcinoma ( 20 ) and ESCC ( 21 ), etc. Moreover, several tumor-related genes (TRE), as the upstream regulator of the PI3K/Akt signaling pathway, were involved in tumor progression and development via regulating cancer cell malignant biological behavior, for instance, upregulation of gene of phosphate and tension homology deleted on Chromosome 10 (PTEN) inhibited tumor progression and enhanced the sensitivity of cancer cell to chemotherapy through blocking the PI3K/Akt signaling pathway ( 22 , 23 ).…”

Hypoxic bone marrow mesenchymal cell‐extracellular vesicles containing miR‐328‐3p promote lung cancer progression via the NF2‐mediated Hippo axis

“…Lung cancer is the leading cause of cancer‐related deaths across the world, imposing a huge burden on healthcare systems in every country 25 . An increasing number of researchers have highlighted the importance of EVs in several lung diseases 26 .…”

“…Lung cancer is the leading cause of cancer-related deaths across the world, imposing a huge burden on healthcare systems in every country. 25 An increasing number of researchers have highlighted the importance of EVs in several lung diseases. 26 In the current study, we aimed to investigate whether EV-delivered miR-328-3p derived from hypoxic BMSCs influences the occurrence and progression of lung cancer and to uncover evidence demonstrating its novel tumour promoting role.…”